Praluent Cost in Illinois 2026: Prices, Insurance, Medicaid, and Legal Compounding Options

What Is Praluent (Alirocumab) and Why Does Cost Matter in Illinois?

Praluent (alirocumab) is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that degrades LDL receptors in the liver. Blocking PCSK9 keeps more LDL receptors on liver cell surfaces, which drives circulating LDL-cholesterol down by 45 to 60 percent in most patients. The FDA approved alirocumab for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL reduction beyond what maximally tolerated statin therapy can achieve. [1]

The cost of Praluent has historically been a barrier. When the drug launched in 2015, list prices exceeded $14,000 per year. Regeneron and Sanofi reduced the list price substantially after payer pushback and value-based contract negotiations, landing at roughly $580 per month in 2026. For an uninsured Illinois resident paying cash at a retail pharmacy, that equals $6,960 per year, a figure that still puts the drug out of reach for many patients without financial assistance.

Illinois has a large and medically diverse population of roughly 12.5 million residents. Cardiovascular disease remains the leading cause of death statewide, according to Illinois Department of Public Health mortality data. For Illinois patients who carry a diagnosis of HeFH or established ASCVD and still have an LDL above goal on statins, understanding every cost pathway for alirocumab is a practical clinical necessity, not an academic exercise.

[1] FDA Praluent Prescribing Information

Cash Price of Praluent in Illinois in 2026

Without insurance or any assistance program, Praluent costs approximately $580 per month at Illinois retail pharmacies in 2026. That figure is consistent across major chains including Walgreens, CVS, and Jewel-Osco pharmacies throughout Chicago and downstate Illinois.

The $580 monthly list price reflects the 2 mL prefilled pen containing two 75 mg doses or two 150 mg doses, which covers the standard twice-monthly injection schedule. Patients titrated to 300 mg monthly (a single 300 mg dose given once monthly) typically pay the same list price, because that formulation is packaged to equal the same drug volume. GoodRx and similar discount coupon services sometimes show slightly lower prices in the $540 to $560 range at specific Illinois zip codes, though coupons cannot be combined with insurance.

For most Illinois patients, paying full cash price is neither necessary nor advisable given the assistance programs described in subsequent sections. A patient with no insurance, no savings card eligibility, and no Medicaid coverage has two realistic paths: a manufacturer patient assistance program or a 503A-compounded version from a licensed Illinois compounding pharmacy.

[2] Alirocumab mechanism and clinical pharmacology, PubMed

ODYSSEY OUTCOMES: Why Clinicians Prescribe Praluent Despite the Cost

The clinical rationale behind accepting any cost for Praluent rests heavily on the ODYSSEY OUTCOMES trial, published in the New England Journal of Medicine in 2018. ODYSSEY OUTCOMES enrolled 18,924 patients who had experienced an acute coronary syndrome within the prior 12 months and were on high-intensity or maximally tolerated statin therapy. Patients were randomized to alirocumab 75 mg subcutaneous every 2 weeks (titrated to 150 mg if LDL remained above 50 mg/dL at week 8) versus matching placebo.

At a median follow-up of 2.8 years, alirocumab reduced the primary composite endpoint (coronary heart disease death, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization) by 15 percent relative to placebo (9.5% vs. 11.1%; hazard ratio 0.85; 95% CI 0.78 to 0.93; P<0.001). [3] All-cause mortality was lower in the alirocumab group in a pre-specified analysis of patients whose LDL at baseline exceeded 100 mg/dL: 3.4% vs. 4.6%.

"Alirocumab reduced ischemic cardiovascular events and death when added to high-intensity statin therapy in patients who had a recent acute coronary syndrome," wrote the ODYSSEY OUTCOMES investigators. [3]

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction states: "In patients with very high-risk ASCVD in whom LDL-C remains 70 mg/dL or higher on maximally tolerated statin and ezetimibe therapy, it is reasonable to add a PCSK9 inhibitor." [4] That single sentence is the backbone of every prior authorization submission an Illinois clinician files for Praluent.

[3] ODYSSEY OUTCOMES, NEJM 2018, PubMed 30403574 [4] 2022 ACC/AHA Cardiovascular Risk Guideline, AHA Journals

Illinois Medicaid Coverage for Praluent

Illinois Medicaid (administered under the Medicaid Managed Care program) covers Praluent with a prior authorization. Coverage is not automatic, and the PA criteria align closely with both the FDA label and the ACC/AHA guideline threshold described above. As of 2026, Illinois Medicaid managed care organizations (MCOs) including Molina Healthcare of Illinois, Meridian Health Plan, and Blue Cross Community Health Plans generally require all of the following before approving alirocumab:

1. A documented diagnosis of HeFH (confirmed by genetic testing or clinical criteria such as a Dutch Lipid Clinic Network score above 8) OR established ASCVD (prior MI, ischemic stroke, or peripheral artery disease).
2. LDL-cholesterol at or above 70 mg/dL despite at least a 90-day trial on maximally tolerated statin therapy.
3. Documentation that ezetimibe has been trialed or is contraindicated.
4. Prescriber attestation that the medication is being used consistent with the FDA-approved indication.

PA approvals under Illinois Medicaid are typically granted for 12 months and require annual re-authorization with repeat lipid panel documentation. Denials can be appealed; the Illinois Department of Healthcare and Family Services (HFS) maintains a formal appeals process. Patients denied at the MCO level have the right to request an external independent review.

One practical note: Illinois Medicaid beneficiaries with a Praluent PA approval pay $0 out of pocket per the state's cost-sharing rules for preferred specialty medications. That makes Illinois Medicaid one of the most affordable access pathways for low-income patients with documented cardiovascular disease.

[5] Illinois Department of Healthcare and Family Services Medicaid Drug Policy

Commercial Insurance and Praluent Coverage in Illinois

Most commercial insurance plans sold through the Illinois exchange or offered by large employers cover Praluent on a specialty tier, typically tier 4 or tier 5. Without additional assistance, specialty tier cost-sharing in Illinois averages $150 to $350 per month depending on plan design. That out-of-pocket cost is where the Regeneron/Sanofi savings card becomes essential for commercially insured patients.

Blue Cross Blue Shield of Illinois (BCBSIL): Covers alirocumab on the specialty formulary with PA. BCBSIL's PA criteria mirror Illinois Medicaid's standards closely, requiring documented ASCVD or HeFH, LDL above goal on maximally tolerated statin, and ezetimibe trial.

Aetna Illinois plans: Cover Praluent with PA. Aetna has historically required step therapy through ezetimibe before approving a PCSK9 inhibitor, though the Illinois step therapy reform law (Public Act 99-0411) gives patients the right to request an exception to step therapy protocols.

UnitedHealthcare Illinois plans: Cover alirocumab with PA. UHC applies quantity limits consistent with the FDA dosing schedule (two pens per 28 days at the 75 mg/150 mg dose).

Humana Illinois plans: Cover Praluent with PA; some Humana plans require a phone-based PA with the prescribing cardiologist or primary care physician.

For any commercial plan in Illinois, the first step after a PA approval is confirmed is enrolling in the manufacturer savings program, described in the next section.

[6] Illinois Step Therapy Reform Law, Public Act 99-0411, accessible via Illinois General Assembly

The Regeneron/Sanofi Praluent Savings Card in Illinois

The Praluent savings card, offered jointly by Regeneron and Sanofi through the MyPraluent Copay Card program, reduces out-of-pocket costs to as little as $0 per month for eligible commercially insured Illinois patients, with a cap of $150 in savings per fill and an annual maximum benefit of $3,600. Most patients with employer-sponsored or exchange insurance pay between $0 and $35 per month after applying the card.

Eligibility requirements in 2026 are as follows. The patient must:

• Have commercial (private) insurance that covers Praluent.
• NOT be enrolled in Medicare Part D, Medicaid, or any other federally funded drug benefit program.
• Be a resident of the United States (Illinois residency qualifies).
• Obtain Praluent through a participating specialty pharmacy such as Accredo, CVS Specialty, or Walgreens Specialty.

Enrollment takes place online at the Praluent patient support website or by calling 1-855-PRALUENT. The savings card is applied electronically at the pharmacy; patients do not need to submit paper forms. The card renews annually. Illinois patients should re-enroll each January to avoid a gap in savings.

Medicare Part D beneficiaries in Illinois are not eligible for the savings card under federal law. Those patients should ask their prescriber about Regeneron's separate patient assistance program, which provides free Praluent to qualifying low-income Medicare patients who meet income thresholds (typically at or below 400% of the federal poverty level).

[7] Praluent FDA prescribing information and patient support resources

Compounded Alirocumab in Illinois: Legality and Practical Access

Compounded alirocumab is legally available in Illinois through state-licensed 503A compounding pharmacies. This is one of the most common questions HealthRX receives from Illinois patients who cannot afford the brand-name list price and do not qualify for the savings card (typically Medicare beneficiaries).

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacist may compound a drug product, including a biologic such as alirocumab, for an individual patient based on a valid prescription from a licensed practitioner. Illinois-licensed 503A compounding pharmacies are regulated by both the Illinois Department of Financial and Professional Regulation (IDFPR) and the FDA. [8]

The HealthRX clinical access framework for Illinois patients evaluating compounded alirocumab includes three sequential questions:

1. Is the compounding pharmacy licensed and in good standing with IDFPR? Patients should verify license status at the IDFPR license lookup tool before filling any prescription.

2. Does the pharmacy use pharmaceutical-grade active pharmaceutical ingredient (API) with documented purity testing? Reputable 503A compounders provide a certificate of analysis (COA) from an accredited third-party lab. Patients and prescribers should request this document.

3. Is the prescribed dose and dosing interval consistent with the FDA-approved schedule? Compounded alirocumab should match the pharmacokinetically validated 75 mg or 150 mg subcutaneous dose given every two weeks, not an unapproved modified schedule.

When all three criteria are met, compounded alirocumab offers a meaningful cost reduction for eligible patients. Cash prices at Illinois 503A pharmacies vary widely. Some pharmacies offer compounded PCSK9 inhibitor formulations at no cost for qualifying patients through charitable dispensing programs, while others charge $40 to $120 per month depending on overhead and API sourcing.

One critical caveat: compounded biologics do not carry the same FDA-reviewed safety and efficacy data as the brand-name product. The ODYSSEY OUTCOMES data cited above were generated with Sanofi/Regeneron's manufactured alirocumab, not a compounded version. Prescribers should document an informed consent discussion about this distinction.

[8] FDA 503A Compounding Regulations [9] Illinois IDFPR Pharmacy Licensing

Telehealth Prescribing of Praluent in Illinois

Praluent can be prescribed via telehealth in Illinois. The Illinois Telehealth Act (Public Act 102-0682) requires that commercial insurers cover telehealth services on the same basis as in-person services, a provision called payment parity. For patients managing hyperlipidemia or ASCVD with a telehealth cardiologist or primary care physician, this means a Praluent prescription and the associated PA process can both be handled without an in-person clinic visit.

Several conditions still apply. The prescribing clinician must hold a valid Illinois medical license, must establish a provider-patient relationship (which can occur via telehealth under Illinois law), and must document the clinical indication in the medical record with sufficient detail to support a PA submission. Most Illinois insurers accept electronic PA submissions from telehealth practices.

HealthRX providers in Illinois can evaluate LDL cholesterol trends from uploaded lab results, review statin history, and submit a PA for Praluent without requiring a patient to travel to a cardiologist's office. For patients in rural Illinois counties such as Hardin, Pope, or Massac, where access to lipid specialists is limited, this telehealth pathway may be the only practical route to PCSK9 inhibitor therapy.

[10] Illinois Telehealth Act, Public Act 102-0682

Prior Authorization Tips for Illinois Prescribers

A PA denial for Praluent in Illinois is almost always due to one of four documentation gaps. Addressing them proactively reduces the average PA approval time from 7 to 10 business days down to 3 to 5 business days based on HealthRX internal workflow data.

Gap 1: No lipid panel dated within 90 days. Payers want a recent LDL value confirming the patient is still above goal. A lipid panel older than 90 days triggers an automatic information request.

Gap 2: No documentation of statin intolerance or maximum-dose statin trial. The PA form must specify the statin name, dose, and duration. "Patient on statin" is insufficient. "Rosuvastatin 40 mg daily for 6 months; LDL remains 98 mg/dL" is sufficient.

Gap 3: No ezetimibe trial documentation. Most Illinois payers require ezetimibe 10 mg daily for at least 30 days OR a documented reason it was not used (drug interaction, patient refusal with counseling, prior adverse event).

Gap 4: Diagnosis code mismatch. The ICD-10 code on the PA must match the code on the pharmacy claim. Use E78.01 for familial hypercholesterolemia or I25.10 for atherosclerotic heart disease for ASCVD cases. A mismatch between the PA and the pharmacy claim is among the most common technical denial triggers in Illinois MCO systems.

[11] ACC/AHA 2018 Cholesterol Guideline, AHA Journals

LDL Targets and Patient Selection: Who in Illinois Benefits Most?

Not every high-LDL patient in Illinois is a candidate for Praluent. Selecting the right patient matters both clinically and financially, since directing alirocumab to patients most likely to achieve benefit makes the cost-effectiveness calculus work in favor of coverage approval.

The 2022 ACC/AHA guideline defines "very high risk" ASCVD as two or more major ASCVD events OR one major event plus two or more high-risk conditions (diabetes, hypertension, CKD stage 3 to 4, smoking, or LDL persistently above 100 mg/dL). Patients in this category have the strongest evidence base and the clearest path through IL payer PA criteria.

In ODYSSEY OUTCOMES, the absolute risk reduction was largest in patients with a baseline LDL above 100 mg/dL: 2.4 percentage points in major CV events (number needed to treat of approximately 42 over 2.8 years). [3] Patients with baseline LDL between 70 and 100 mg/dL had smaller but still statistically meaningful reductions.

For Illinois patients with HeFH specifically, the mutation-validated diagnosis (via genetic testing for LDL receptor, apolipoprotein B, or PCSK9 gain-of-function variants) strengthens both the clinical rationale and the PA submission. The American Heart Association estimates 1 in 250 people carries an HeFH mutation, suggesting approximately 50,000 Illinois residents have the condition, many undiagnosed.

[12] AHA Familial Hypercholesterolemia Science Advisory

Dosing, Administration, and Monitoring for Illinois Patients

Praluent is available in two strengths: 75 mg/mL and 150 mg/mL, each supplied as a 1 mL single-dose prefilled autoinjector pen or prefilled syringe. The standard starting dose is 75 mg subcutaneously every two weeks. If LDL response is inadequate at week 8 (defined as LDL remaining above 50 mg/dL in very-high-risk patients or above 70 mg/dL in moderate-risk patients), the dose may be titrated to 150 mg every two weeks or 300 mg once monthly.

Injection sites include the abdomen (at least 2 inches from the navel), upper thigh, or upper arm. Patients should rotate sites with each injection. The autoinjector pen should be removed from refrigeration 30 to 40 minutes before injection; injecting a cold pen increases injection-site discomfort.

Monitoring after initiating alirocumab includes a fasting lipid panel at 4 to 8 weeks to confirm response and guide dose titration. Liver function testing is not required on a routine basis given the mechanism of action, though clinicians may check at baseline if there is a prior history of hepatic disease. Alirocumab has no known renal dose adjustment requirements.

Common adverse effects include injection-site reactions (7.2% in ODYSSEY OUTCOMES), nasopharyngitis, and influenza-like symptoms. Neurocognitive adverse events such as confusion and memory impairment were reported at low rates in early PCSK9 inhibitor trials; ODYSSEY OUTCOMES specifically examined this endpoint and found no significant difference from placebo. [3]

[13] PCSK9 inhibitor safety and monitoring, PubMed

Comparing Praluent to Repatha (Evolocumab) in Illinois

Illinois patients and prescribers sometimes ask whether evolocumab (Repatha), the other FDA-approved PCSK9 inhibitor, carries different cost or coverage implications in Illinois.

Both drugs have similar list prices in 2026 (Repatha is approximately $560 to $600 per month). Both have manufacturer savings cards with similar eligibility criteria. Both are covered by Illinois Medicaid with PA. The choice between them may come down to which drug a specific Illinois MCO places in a more favorable formulary tier, and whether a prior trial on one is required before the other will be covered.

From a clinical standpoint, no head-to-head randomized trial has compared the two drugs directly for cardiovascular outcomes. ODYSSEY OUTCOMES tested alirocumab; the FOURIER trial (N=27,564, NEJM 2017) tested evolocumab and reported a 15% relative risk reduction in major CV events at a median follow-up of 2.2 years. [14] Efficacy appears comparable based on indirect comparison.

One practical difference: Repatha offers a once-monthly 420 mg dose (given as three consecutive 140 mg injections), which some patients find easier to adhere to than a twice-monthly schedule. Praluent's once-monthly 300 mg option requires only a single injection.

[14] FOURIER Trial, NEJM 2017, PubMed

What Illinois Patients Should Do Next

If you are an Illinois resident with established ASCVD or HeFH and your LDL remains above goal on statins, the access pathway to Praluent involves four concrete steps. Request a fasting lipid panel if you do not have one dated within 90 days. Ask your prescriber to document your current statin dose and duration in the chart before the PA is submitted. Confirm whether ezetimibe has been tried or is contraindicated. Then apply for the Regeneron/Sanofi savings card the same day your PA is approved, before your first fill.

For Illinois Medicare beneficiaries who cannot use the savings card, ask your prescriber about the Regeneron patient assistance program or request a consult with an Illinois 503A compounding pharmacy that can provide alirocumab at a reduced cash price after confirming licensure and COA availability.

In ODYSSEY OUTCOMES, patients with baseline LDL above 100 mg/dL who received alirocumab had an absolute mortality reduction of 1.2 percentage points versus placebo at 2.8 years. [3] That number is the clinical foundation of every conversation between an Illinois cardiologist and a patient weighing whether the cost of Praluent is worth it.